TLR2 and acute myeloid leukemia: To further verify whether TLR2 targeting mediates endocytosis, endocytosis inhibitor amiloride (3 mM) was used to treat AML cells 12 h in advance, and then rhodamine-labeled TLR2 pep-orid-liposome was co-incubated for 2 h.